Stocks Health care RVMD
NASDAQ · Health careRevolution Medicines, Inc. (RVMD)
It posted a net loss of $1.8B. In fiscal 2025 capital spending exceeded operating cash flow by $913.7M. At June 30, 2026 it held $815.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What Revolution Medicines, Inc. does
Revolution Medicines is a clinical-stage oncology company that develops targeted therapies for cancer patients. The company focuses on developing small-molecule inhibitors that target the RAS pathway, a biochemical signalling pathway frequently mutated in difficult-to-treat cancers such as pancreatic, non-small cell lung, and colorectal cancers. Its shares trade on NASDAQ under the ticker RVMD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$1.1B | -$5.95 | -$913.7M |
| 2024 | $0 | -$600.1M | -$3.58 | -$567.7M |
| 2023 | $11.6M | -$436.4M | -$3.86 | -$358.3M |
| 2022 | $35.4M | -$248.7M | -$3.08 | -$235.2M |
| 2021 | $29.4M | -$187.1M | -$2.57 | -$153.7M |
| 2020 | $43M | -$108.2M | -$2.01 | -$103M |
Latest SEC filings
What Revolution Medicines, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 1, 2026
- August 26, 2026Other event 8-K
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 5, 2026
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- June 22, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
Questions about RVMD
What does Revolution Medicines, Inc. do?
Revolution Medicines is a clinical-stage oncology company that develops targeted therapies for cancer patients. The company focuses on developing small-molecule inhibitors that target the RAS pathway, a biochemical signalling pathway frequently mutated in difficult-to-treat cancers such as pancreatic, non-small cell lung, and colorectal cancers. Its shares trade on NASDAQ under the ticker RVMD.
Is Revolution Medicines, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $1.8B.
When did Revolution Medicines, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the planned insider sale from September 25, 2026.
Similar companies
Follow RVMD
Get an email when Revolution Medicines, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow RVMD: get an email when it filesWhere the numbers come from
Financial figures are the values Revolution Medicines, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.